Northstar Medical Radioisotopes, engaged in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, announced a corporate update highlighting progress across its key programs during the past twelve months, and upcoming milestones.

Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes said, “Our plans to ensure reliable, environmentally friendly, non-uranium based radioisotope supply for the United States continue to progress. RadioGenix® System (technetium Tc 99m generator) utilization is increasing. We are well on our way to having dual production and processing pathways for Mo-99 to ensure additional domestic capacity and supply security to best meet customer demand. Our Mo-99 facility expansions are nearing completion and moving to the final phase of activities required for licensure and FDA approval”.. 

To read more please visit:

NorthStar Medical Radioisotopes provides Updates on Corporate progress and Progress and Upcoming Milestones

Source: NorthStar